TP53 and non-small cell lung carcinoma: A cohort study, which enrolled 16 patients with early-stage EGFR-mutant NSCLC, revealed that multiple truncal alterations, including TP53 mutations and loss of CDKN2A and RB1, were associated with high genomic instability and a higher proportion of co-existing genomic alterations44.